AVM Biotechnology reposted this
AVM Biotechnology's clinical research has uncovered the body’s reserve immune system; special bispecific T lymphocytes and Natural Killer T cells that express both the gamma delta TCR and the invariant TCR. These cells are not present anywhere in the healthy body. The production of these cells is triggered by serious disease such as cancer, autoimmunity and infectious disease when the regular immune system is not sufficient. Only 20% of the population gets cancer even though everyone has cells that mutate, thus 80% must be able to produce and release these unique immune cells. From the 71 patients and 220 infusions of AVM0703 we have learned that 10% of people with cancer produce but do not release these cells because anti-cancer responses become evident immediately, sometimes within 30 minutes of the start of the one hour intravenous infusion. About 65% of people with cancer require 3-21 days for response, and thus were not able to produce the cells until after AVM0703. The patients being treated at this stage of the development path are imminently terminal, and unfortunately, 25% have little to no response to AVM0703. As AVM0703 moves to earlier lines of therapy, in combination with standard of care, we hypothesize that the number responding will increase dramatically, and that AVM0703 plus standard of care will improve response rates, reduce the total exposure to toxic cancer therapies and significantly improve short and long term toxicities, potentially eliminating the late cardiotoxicity, neurotoxicity and secondary malignancies that cancer survivors face.